Credit Suisse Upgrades Salix (Nasdaq: SLXP) to Outperform
Credit Suisse upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Neutral to Outperform.
Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs used in the treatment of gastrointestinal disorders in the United States.
Related Categories
UpgradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
